Vemurafenib Recruiting Phase 2 Trials for Recurrent Central Nervous System Neoplasm / Stage III Soft Tissue Sarcoma AJCC v7 / Recurrent Childhood Soft Tissue Sarcoma / Rhabdoid Tumors / Stage IV Childhood Non-Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Advanced Malignant Solid Neoplasm / Recurrent Hepatoblastoma / Recurrent Childhood Medulloblastoma / Stage III Osteosarcoma / Stage IVB Osteosarcoma AJCC v7 / Stage III Childhood Non-Hodgkin Lymphoma / Recurrent Gliomas / Stage III Osteosarcoma AJCC v7 / Malignant Gliomas / Stage IVB Osteosarcoma / Recurrent Ewing Sarcoma / Recurrent Childhood Rhabdomyosarcoma / Refractory Childhood Malignant Germ Cell Tumor / Recurrent Osteosarcoma / Stage IV Osteosarcoma / Stage IVA Osteosarcoma / Refractory Malignant Solid Neoplasm / Stage IV Soft Tissue Sarcoma / Langerhans Cell Histiocytosis (LCH) / Recurrent Neuroblastoma / Childhood Langerhans Cell Histiocytosis / Stage IVA Osteosarcoma AJCC v7 / refractory Langerhans cell histiocytosis / Recurrent Malignant Solid Neoplasm / Stage IV Soft Tissue Sarcoma AJCC v7 / Wilms' tumor / Recurrent Peripheral Primitive Neuroectodermal Tumor / Malignant Lymphomas / Recurrent Childhood Ependymoma / Juvenile Xanthogranuloma / Stage IV Osteosarcoma AJCC v7 / Refractory Central Nervous System Neoplasm / Recurrent Childhood Malignant Germ Cell Tumor / Refractory Neuroblastoma / Histiocytic Sarcoma (HS) / Recurrent Langerhans Cell Histiocytosis / Stage III Soft Tissue Sarcoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03155620Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders